Physician profile
Jonathan S Rogers
NPI 1619012291
$8,434.86
in general payments reported to CMS, 2019-2025
43 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,093 · 2020: $686 · 2021: $974 · 2022: $1,152 · 2023: $1,584 · 2024: $879 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,530.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,048.11 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $978.77 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $633.14 | 2020-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $629.00 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $608.73 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $461.30 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $425.30 | 2019-2024 | Confirm Rx, Thoratec Heartmate 3 Lvas Implant Kit, Tendril |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.04 | 2021-2024 | Jardiance |
| Esperion Therapeutics, INC. | $299.83 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $299.41 | 2021-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $287.85 | 2019-2023 | Watchman |
| Heartflow, INC. | $235.05 | 2025 | |
| Sanofi-Aventis U.S. LLC | $233.19 | 2019-2023 | |
| Irhythm Technologies, INC. | $227.66 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Astrazeneca Pharmaceuticals LP | $206.34 | 2019-2025 | Farxiga |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $196.06 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $153.07 | 2019-2024 | Evkeeza |
| Bardy Diagnostics, INC. | $130.57 | 2020-2022 | |
| Kestra Medical Technology Services, INC. | $121.76 | 2023-2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $96.16 | 2023-2025 | Amvuttra, Onpattro |
| Amarin Pharma, INC. | $77.31 | 2019-2020 | |
| Akcea Therapeutics, INC. | $75.96 | 2019 | |
| Baxter Healthcare | $70.51 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Philips North America LLC | $63.78 | 2024-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und, (Ck4) Mcot |
| Scpharmaceuticals INC. | $57.14 | 2023-2024 | |
| Itamar Medical INC | $53.57 | 2021-2024 | Watchpatone |
| Kiniksa Pharmaceuticals, LTD. | $44.66 | 2021-2023 | Arcalyst |
| Atricure, INC. | $40.88 | 2019-2022 | |
| Bridgebio Pharma, INC. | $38.78 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $38.78 | 2024 | Arcalyst |
| Abiomed | $38.71 | 2024-2025 | |
| Lundbeck LLC | $34.64 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $32.15 | 2019-2022 | |
| Gilead Sciences, INC. | $31.83 | 2019 | |
| Medtronic Vascular, INC. | $27.88 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $19.67 | 2023 | Inpefa |
| Medtronic, INC. | $19.04 | 2022 | |
| Glaxosmithkline, LLC. | $18.75 | 2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $18.18 | 2025 | |
| Medicomp INC | $18.10 | 2024 | Telepatch Cardiac Monitor |
| Astellas Pharma US INC | $14.35 | 2019 | |
| Inspire Medical Systems, INC. | $14.27 | 2024 | Inspire |
| Arbor Pharmaceuticals, INC. | $12.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.